[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The Hospital for Sick Children\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":683},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,70,0,25,[9,49,75,113,137,163,192,223,252,274,297,319,346,374,405,432,457,484,510,536,559,582,602,635,654],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100635707","medlypeds-feasibility-study-100635707",false,"NCT07556185","MedlyPeds Feasibility Study","MedlyPeds Feasibility Study: A Mobile, Smartdevice Based Telemonitoring for Pediatric Heart Disease, a Prospective Cohort Study","Inclusion Criteria:\n\n1. Consent provided.\n2. Aged 8-18 years of age.\n3. Ability to comply with using Medly (ex. able to stand on the weight scale, able to answer symptom questions, etc.)\n4. Followed at the Hospital for Sick Children Cardiology Clinic for any of the following reasons:\n\n   1. Heart failure of any etiology\n   2. Congenital heart disease\n   3. Acquired heart disease (eg. Kawasaki disease, rheumatic heart disease, connective tissue disorders etc)\n   4. Pulmonary hypertension\n   5. Post-cardiac surgery including heart transplant and ventricular assist devices\n\nExclusion Criteria:\n\n1. Unable to read or write in English.\n2. Participating in another clinical trial that may confound the results.\\* \\*Participant may be re-screened for eligibility at a later date.","ALL","8 Years","18 Years",{"count":21,"type":22},30,"ESTIMATED","INTERVENTIONAL",[25],"NA","SickKids and UHN have developed MedlyPeds which is a smart phone application designed to remotely monitor patients with heart disease. This is a feasibility study which will enroll up to 30 patients with different types of heart disease to see which patient types may benefit the most from MedlyPeds if it were to be used for clinical monitoring. The study is gathering feedback about the app from patients, parents and clinicians to confirm how it needs to be modified to better serve the purpose in a future trial.",[28,29,30,31,32],"Pediatric Heart Failure","Congenital Heart Disease (CHD)","Acquired Heart Disease","Pulmonary Hypertension","Post Cardiac Surgery",[34,35],"Medly","Telemonitoring","RECRUITING","2026-06-23",{"date":39,"type":40},"2026-06-26","ACTUAL",{"date":42,"type":22},"2026-07",{"date":44,"type":22},"2029-12",{"name":46,"class":47},"The Hospital for Sick Children","OTHER",1,{"id":50,"slug":51,"hasResults":12,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":12,"sex":17,"minAge":56,"maxAge":19,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":48},"100556488","weaning-is-winning-wewin-study-100556488","NCT06525753","Weaning is Winning? (WeWin Study)","Weaning is Winning? (WeWin Study): Are Parenteral Nutrition (PN) Graduates Growing up Healthy?","Inclusion Criteria:\n\n* Parenteral Nutrition graduates for at least 1 year, with a history of intestinal failure.\n* Age \\\u003C18 years at time of inclusion.\n\nExclusion criteria:\n\n* No consent provided.","0 Years",{"count":58,"type":22},120,"OBSERVATIONAL","We propose a multicenter prospective study on pediatric patients with intestinal failure (IF) who weaned off parenteral nutrition (PN).",[62,63],"Intestinal Failure","Parenteral Nutrition",[65,66],"Quality of Life","Pediatric","2026-06-19",{"date":69,"type":40},"2026-06-24",{"date":71,"type":40},"2024-06-01",{"date":73,"type":22},"2034-06-01",{"name":46,"class":47},{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":12,"sex":17,"minAge":83,"maxAge":19,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":86,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":48},"100638343","cpap-vs-high-flow-nasal-cannula-for-treating-sleep-apnea-in-children-100638343","NCT07600333","CPAP vs High-Flow Nasal Cannula for Treating Sleep Apnea in Children","Continuous Positive Airway Pressure vs High Flow Nasal Cannula for the Treatment of OSA in Children","CHOSA","Inclusion Criteria:\n\n* Aged 2 to 18 years\n* Diagnosed with moderate to severe obstructive sleep apnea, defined as an obstructive apnea-hypopnea index (OAHI) ≥5 events\u002Fhour, confirmed by an in-laboratory polysomnography within the previous 6 months\n* Deemed to require Continuous Positive Airway Pressure (CPAP) therapy as part of usual clinical care\n* Ability of the participant and\u002For parent or legal guardian to provide informed consent (and assent when applicable)\n\nExclusion Criteria:\n\n* Predominant or pathological central sleep apnea (central apnea-hypopnea index ≥5 events\u002Fhour)\n* Chronic respiratory failure or medical conditions requiring ventilatory support with a set respiratory rate (e.g., neuromuscular disease requiring bilevel ventilation with a backup rate)\n* Hypoventilation requiring non-invasive ventilation with a set respiratory rate\n* History of pneumothorax or pneumomediastinum\n* Uncontrolled gastroesophageal reflux and\u002For recurrent vomiting\n* Uncontrolled oral secretions\n* Prior use of CPAP or High-Flow Nasal Cannula therapy for treatment of obstructive sleep apnea within the previous 12 months","2 Years",{"count":85,"type":22},258,[25],"This study is looking at two different treatments for obstructive sleep apnea (OSA) in children. OSA is a sleep condition where breathing repeatedly stops and starts during sleep, which can affect a child's health, behavior, learning, and quality of life.\n\nChildren with moderate-to-severe OSA who cannot be treated with surgery are often prescribed Continuous Positive Airway Pressure (CPAP). CPAP uses a mask worn during sleep to deliver pressurized air and keep the airway open. Although CPAP is effective, many children have difficulty using it regularly because it can feel uncomfortable or hard to tolerate.\n\nThis study compares CPAP with another treatment called High-Flow Nasal Cannula (HFNC). HFNC delivers warm, humidified air through soft nasal prongs and may be more comfortable and easier for children to use while still helping keep the airway open during sleep.\n\nChildren aged 2 to 18 years with moderate-to-severe OSA will be randomly assigned to use either CPAP or HFNC at home during sleep for 3 months. The study will measure how much each treatment is used, how well it improves sleep-related symptoms and quality of life, how comfortable it is for children, and how it affects caregivers.\n\nThe goal of this study is to find out whether HFNC is a comfortable and effective alternative to CPAP for treating obstructive sleep apnea in children.",[89],"Obstructive Sleep Apnea (OSA)",[91,92,93,94,95,96,97,98,99,100,101,102,103],"obstructive sleep apnea","pediatric obstructive sleep apnea","children","adolescents","continuous positive airway pressure","CPAP","High Flow nasal cannula","HFNC","Sleep-disordered breathing","adherence","quality of life","home sleep therapy","randomized controlled trial","NOT_YET_RECRUITING","2026-05-14",{"date":107,"type":40},"2026-05-20",{"date":109,"type":22},"2026-06-01",{"date":111,"type":22},"2031-12",{"name":46,"class":47},{"id":114,"slug":115,"hasResults":12,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":12,"sex":17,"minAge":120,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":23,"phases":124,"briefSummary":125,"conditions":126,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":4},"100637973","integrating-an-ai-driven-hydronephrosis-decision-making-tool-100637973","NCT07581223","Integrating an AI-Driven Hydronephrosis Decision-Making Tool","Integration of a Hydronephrosis AI-Driven Decision-Making Tool Into Clinical Practice: A Clinical Trial","Inclusion Criteria:\n\n* Seen for HN in-person in the Pediatric Urology clinic with ultrasound scans taken at SickKids\n* New and follow-up patients 0-24 months.\n\nExclusion Criteria:\n\n* Older than 24m\n* Concurrent urinary tract anomalies (duplex configurations; PUV etc.)\n* History of renal surgical intervention (post-op patients)","0 Months","24 Months",{"count":123,"type":22},322,[25],"Hydronephrosis is a common congenital kidney anomaly. While most cases resolve on their own, some require surgery. Clinicians rely on repeated ultrasounds and sometimes invasive tests to decide if surgery is needed, but predicting outcomes is difficult. Researchers at SickKids developed an AI model that analyzes ultrasound images to assist in diagnosing and managing hydronephrosis. This study tests how well the AI integrates into real-world care. Clinicians will first make care decisions without AI and then review the AI's prediction before deciding whether to change their plan. A separate expert, unaware of whether AI influenced the first clinician's plan, will make the final decision to ensure care remains unchanged. The study will assess whether AI improves decision-making, reduces unnecessary tests, and fits into clinical workflows. If successful, the AI model could serve as a complementary tool to make diagnoses more efficient and precise while minimizing invasive procedures.",[127,128],"Hydronephrosis","Hydronephrosis Congenital","2026-05-06",{"date":131,"type":40},"2026-05-12",{"date":133,"type":22},"2026-08-01",{"date":135,"type":22},"2027-01-31",{"name":46,"class":47},{"id":138,"slug":139,"hasResults":12,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":12,"sex":17,"minAge":144,"maxAge":145,"enrollmentInfo":146,"targetDuration":4,"studyType":23,"phases":148,"briefSummary":149,"conditions":150,"keywords":152,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":48},"100506949","home-initiation-of-noninvasive-positive-pressure-ventilation-in-children-with-medical-complexity-100506949","NCT05881031","Home Initiation of Noninvasive Positive Pressure Ventilation in Children With Medical Complexity","Single Site Feasibility and Safety Study of Home Initiation of Noninvasive Positive Pressure Ventilation in Children With Medical Complexity","Inclusion Criteria:\n\n1. Age 5-17 years old\n2. Newly prescribed NiPPV\n3. Tolerated awake NiPPV trial\n4. Provides informed consent\n\nExclusion Criteria:\n\n1. Cardiac disease at risk of hemodynamic instability with NiPPV initiation (eg cardiac dysfunction (ejection fraction \\\u003C45%), pulmonary hypertension (mean pulmonary artery pressure ≥ 20 mmHg on right heart catheterization or suggestive echocardiogram findings in the opinion of a pediatric cardiologist), or single ventricle)\n2. At high risk of complications with NiPPV in the opinion of the child's physician (eg pneumothorax and aspiration risk)\n3. Severe sleep disordered breathing with peak CO2 ≥ 60mmHg or apnea-hypopnea index (AHI)≥ 30\u002Fhr (AHI measures the number of respiratory events per hour)\n4. Participation in concurrent research study that may affect NiPPV adherence (proposed primary outcome of full study)\n5. Exclusion of study participants if the caregiver or participant is not English speaking","60 Months","215 Months",{"count":147,"type":22},24,[25],"Children with medical complexity (CMC) often have trouble breathing at night and need to use a breathing machine. This breathing machine is called noninvasive positive pressure ventilation (NiPPV). The use of NiPPV has been shown to improve quality of life and survival in children. Before it is used, NiPPV must first be tested to see what the correct 'machine settings' are for each child. This is usually done in the sleep laboratory at the hospital during a one-night stay. However, sleep studies in the hospital are disruptive and hard for CMC and their families because of the new environment and limited access to the equipment, supplies, comfort items and the routine their child has at home. Patients and families would prefer to start NiPPV at home but there needs to be more research on this to make sure it is possible and safe. This study will evaluate a new model of care to start NiPPV in the home. CMC aged 5-17 years old and starting NiPPV will be assigned at random, like a coin toss, to start NiPPV in the home or to start NiPPV in the sleep laboratory. The investigators will assess the feasibility and safety of the two ways to start NiPPV. This study will be the first step towards developing a study to evaluate if home NiPPV starts are effective. Starting NiPPV at home has the potential to improve the use of NiPPV (ie early adherence predicts long-term use) resulting in both medical benefits as well as improved quality of life for CMC and their families.",[151],"Sleep-Disordered Breathing",[153,154],"noninvasive ventilation","home mechanical ventilation","2026-05-03",{"date":157,"type":40},"2026-05-07",{"date":159,"type":40},"2023-06-21",{"date":161,"type":22},"2027-12-01",{"name":46,"class":47},{"id":164,"slug":165,"hasResults":12,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":169,"eligibilityCriteria":170,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":171,"targetDuration":4,"studyType":23,"phases":173,"briefSummary":174,"conditions":175,"keywords":179,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":191},"100552550","feasibility-of-a-diet-intervention-for-juvenile-arthritis-100552550","NCT06474546","Feasibility of a Diet Intervention for Juvenile Arthritis","The Role of Diet, as Mediated by the Gut Microbiome, on Childhood Arthritis Disease Activity: a Feasibility Intervention Study","DIGEST-JA","Inclusion Criteria:\n\n* Ages 8-18 years\n* Diagnosis of JIA (excluding systemic JIA, enthesitis-related arthritis, and rheumatoid factor (RF) positive polyarthritis) as per International League of Associations for Rheumatology (ILAR) criteria. (For this feasibility study, there will be no requirement for any particular level of disease activity.)\n* Subjects on stable treatment - i.e., any medical treatment with disease-modifying antirheumatic drugs (DMARDs) and\u002For systemic or intraarticular corticosteroids, has been unchanged for 8 weeks, and is unlikely to change for 12 weeks as judged by the treating physician.\n* Willingness to provide stool samples.\n* English or French fluency adequate to answer the study questionnaires, and participate in diet instruction, as judged by the enrolling physician.\n\nExclusion Criteria:\n\n* Documented specific food allergies, celiac disease.\n* Co-morbidities that might impact the tolerability of the study diet, e.g., type I diabetes, peptic ulcer disease, etc.",{"count":172,"type":22},54,[25],"Families of children with arthritis are highly interested in the benefits of diet to improve their child's disease and future health outcomes. Previous research shows that the germs - bacteria and other organisms - that live in the intestines (gut microbiome) are important to how well immune systems work, and that what people eat changes their gut microbiome. The investigators want to study whether a certain diet - based on the principles of the Mediterranean Diet - will improve arthritis for children and whether it was changes in the microbiome that led to improvement.\n\nFifty-four participants in this study will change their diet for an 8-week period, and will have the option of remaining on the diet for an additional 4 weeks. At three time points during the study (beginning, 8 weeks, and 12 weeks), participants will provide stool and blood samples, will complete questionnaires about diet and other aspects of lifestyle and health, and will complete a disease assessment by a clinician. From collecting all these samples and information, the investigators will be able to determine if the diet was successful in improving disease activity in children with arthritis and if the gut microbiome was changed as well.\n\nThis study will help the investigators figure out if a larger, and more definitive, study like this is possible to do in children with arthritis and will help the investigators design a bigger multinational study to confirm how diet affects disease outcomes and the microbiome in children with arthritis. If successful, this research will provide scientific knowledge to help families make their way through this difficult to- navigate topic.",[176,177,178],"Arthritis, Juvenile","Arthritis, Childhood","Juvenile Idiopathic Arthritis",[180,181,182],"arthritis","diet","microbiome","2026-04-29",{"date":185,"type":40},"2026-05-05",{"date":187,"type":40},"2025-04-07",{"date":189,"type":22},"2028-10",{"name":46,"class":47},7,{"id":193,"slug":194,"hasResults":12,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":4,"eligibilityCriteria":198,"healthyVolunteers":12,"sex":17,"minAge":199,"maxAge":200,"enrollmentInfo":201,"targetDuration":4,"studyType":23,"phases":203,"briefSummary":204,"conditions":205,"keywords":208,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":48},"100488152","safety-and-pk-pd-study-of-oral-l-cit-in-preterm-infants-with-bpdph-and-nec-100488152","NCT05636397","Safety and PK-PD Study of Oral L-CIT in Preterm Infants With BPD±PH and NEC","A Phase I, Safety and Pharmacokinetics\u002FPharmacodynamics Study of Oral L-CIT Supplementation in Preterm Infants With BPD±PH and NEC","Arm 1: BPD±PH:\n\nInclusion Criteria:\n\n* Born ≤ 30 weeks at birth\n* Post-menstrual age (PMA) ≥ 32 weeks\n* Echocardiographic evidence of PH for infants with BPD+PH.\n* On invasive or non-invasive ventilation with RSS \\>2.0 for \\>12hours\u002Fday for at least 48 hours as an early predictor of evolving BPD\n* Informed written consent (parents\u002Fsubstitute decision maker)\n\nExclusion Criteria\n\n* Congenital Heart Disease \\[Exceptions: small atrial septal defect (ASD), small ventricular septal defect (VSD), small patent ductus arteriosus (PDA)\\]\n* Infants with pulmonary vein stenosis\n* Concurrent sepsis with hemodynamic instability\n* Infants considered likely to die within next 7 days\n* Any other condition that, in the opinion of the investigator, may adversely affect the infant's ability to complete the study or its measures or pose significant risk to the infant\n\nArm 2: surgical NEC\n\nInclusion Criteria:\n\n* Born ≤ 30 weeks at birth\n* Recovering from Stage IIIb NEC as per modified Bell's staging (pneumoperitoneum requiring surgery)\n* Tolerating 50 ml\u002Fkg\u002Fday of enteral feeds\n* Informed written consent (parents\u002Fsubstitute decision maker)\n* Considered medically stable by clinical team\n\nExclusion Criteria\n\n* Congenital heart disease (except small ASD, small VSD and non hsPDA)\n* Pulmonary vein stenosis\n* Concurrent sepsis with hemodynamic instability\n* Likely to die within next 7 days\n* Other condition significantly affecting pulmonary function independent of prematurity or NEC","1 Month","6 Months",{"count":202,"type":22},36,[25],"The purpose of this study is to evaluate the safety and explore the PK\u002FPD of L-CIT supplementation in preterm infants to prevent the development of inflammatory pathways initiated by low levels of plasma CIT, specifically in preterm infants with post-surgical NEC and BPD±PH.",[206,31,207],"BPD - Bronchopulmonary Dysplasia","NEC",[209,210,211,212,213,214],"BPD±PH","surgical NEC","L-Citrulline","Pharmacokinetic profile","Pharmacodynamic profile","Preterm neonates","2026-04-28",{"date":217,"type":40},"2026-05-04",{"date":219,"type":40},"2023-11-01",{"date":221,"type":22},"2028-03",{"name":46,"class":47},{"id":224,"slug":225,"hasResults":12,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":4,"eligibilityCriteria":229,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":19,"enrollmentInfo":230,"targetDuration":4,"studyType":23,"phases":232,"briefSummary":233,"conditions":234,"keywords":239,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":48},"100584222","pact-involvement-in-cardiology-patients-100584222","NCT06886529","PACT Involvement in Cardiology Patients","Early PACT Involvement in Cardiology Patients Using Machine Learning","Inclusion Criteria:\n\n* Pediatric inpatients admitted to cardiology\n\nExclusion Criteria:\n\n* Expected to be discharged prior to midnight on the day of admission",{"count":231,"type":22},1000,[25],"The goal of this trial is to determine the effectiveness of a machine-learning (ML) model predicting a serious cardiac event within the next three months, when compared pre- versus post-deployment, in pediatric cardiac inpatients. The main questions it aims to answer are whether deployment of the ML model:\n\n1. Increases PACT consultation within the next three months among admissions without PACT involvement in the previous 100 days\n2. Increases PACT consultation or visit within the next three months among those who experience a serious cardiac event during this period\n3. Decreases time to PACT consultation or visit among those seen by PACT during this period\n4. Decreases the incidence of death in the intensive care unit (ICU)\n5. Increases documentation of goals of care\n\nHigh-risk cardiology patients will be identified by an ML model each morning. If the patient has been seen by the PACT team within the past year, the update will go to the PACT team members. If the patient hasn't been seen by the PACT team, the email will be sent to the cardiology physician in charge of the patient. This physician will decide whether a PACT consultation is necessary based on their clinical judgment. If so, a referral will be made using the usual process. Outcomes of the identified patients will be compared pre- and post-deployment.",[235,236,237,238],"Machine Learning","Cardiovascular Outcome","Pediatric Palliative Care","Pediatric Cardiology",[101,240,241,242,243],"cardiovascular outcomes","machine learning","prediction models","pediatric","2026-04-22",{"date":246,"type":40},"2026-04-23",{"date":248,"type":40},"2025-10-16",{"date":250,"type":22},"2027-10-16",{"name":46,"class":47},{"id":253,"slug":254,"hasResults":12,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":4,"eligibilityCriteria":258,"healthyVolunteers":259,"sex":17,"minAge":260,"maxAge":261,"enrollmentInfo":262,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":264,"conditions":265,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":268,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":48},"100468926","adaptive-optics-retinal-imaging-in-inherited-and-acquired-retinal-disorders-100468926","NCT05386134","Adaptive Optics Retinal Imaging in Inherited and Acquired Retinal Disorders","Adaptive Optics Imaging in Retinal Disorders","Inclusion Criteria:\n\n1. Consent provided\n2. Aged 5 - 70 years\n3. Diagnosed with well documented retinal disorder\n\nControl group Inclusion Criteria:\n\n1. Subjects aged 5 years - 70 years with normal eye examination.\n2. Patients with strabismus and otherwise normal visual acuity and eye examination\n3. Patients with unilateral eye diseases such as cataract, with a normal eye exam in the fellow eye.\n\nExclusion Criteria:\n\n1. Inability of the subject to maintain a stable position while seated\n2. Uncontrolled nystagmus, trembling or movements of the eyes or the head\n3. Presence of cataract or any opacity in the front of the eye that obscures retinal imaging\n4. Any general disease such neurological disease which could affect vision and the retina.\n5. History of previous uveitis, glaucoma, previous intra-ocular surgery or photodynamic therapy\n6. High refractive errors (\\> +15D or \\\u003C -15D) that cannot be corrected by the adaptive optics system.\n7. Patients who have a history of photosensitivity or take any medicine that cause photosensitivity as a side effect\n8. Patients who are aphakic after cataract surgery",true,"5 Years","70 Years",{"count":263,"type":22},200,"This is a Prospective Observational study. The aim of the study is to understand the underlying photoreceptor, retinal pigment epithelium or retinal vascular aberrations in inherited and acquired retinal disorders. The study would use adaptive optics (AO) technology to assist in-vivo visualization of these retinal structures and ascertain changes from normal. Further, by using the AO imaging in patients before and after treatments, this study aims to better understand the effect of various interventions and develop AO as an outcome measure in various retinal disorders.",[266,267],"Genetic Disease","Inherited Disease",{"date":215,"type":40},{"date":270,"type":40},"2022-06-13",{"date":272,"type":22},"2033-06-13",{"name":46,"class":47},{"id":275,"slug":276,"hasResults":12,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":4,"eligibilityCriteria":280,"healthyVolunteers":12,"sex":17,"minAge":281,"maxAge":282,"enrollmentInfo":283,"targetDuration":4,"studyType":23,"phases":285,"briefSummary":286,"conditions":287,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":48},"100521873","online-support-4-chd-kids--caregivers-100521873","NCT06075251","Online Support 4 CHD Kids & Caregivers","Stepped-Care Online Parent Support Following Congenital Heart Disease: A Randomized Control Trial","Inclusion Criteria:\n\n* Parent of a child aged 3 to 9 years with history of congenital heart disease\n* Parent of a patient at The Hospital for Sick Children (SickKids)\n* Resident of Ontario, Canada\n\nExclusion Criteria:\n\n* Significant major medical issues requiring ongoing inpatient care (e.g., children participating in significant surgical or inpatient treatment)\n* Current participation in an equivalent family\u002Fparent therapy program (e.g., Incredible Years Parenting Program (IYPP), Positive Parenting Program (Triple P))\n* Previous participation in an I-InTERACT-North pilot study","3 Years","9 Years",{"count":284,"type":22},382,[25],"This study will evaluate a virtual mental health parenting stepped-care intervention (I-InTERACT-North) to determine if the program works to improve positive parenting skills and child behaviour among families with children born with Congenital Heart Disease (CHD). Recruitment will target children ages 3-9 years old from SickKids. We will also evaluate the acceptability and feasibility of the program among children and families to inform future delivery and multi-site trials. Results will evaluate whether I-InTERACT-North can improve parenting and child behaviour in these families and inform future best clinical practices for this population.",[288],"Congenital Heart Disease","2026-04-21",{"date":291,"type":40},"2026-04-24",{"date":293,"type":40},"2024-02-15",{"date":295,"type":22},"2028-12-31",{"name":46,"class":47},{"id":298,"slug":299,"hasResults":12,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":4,"eligibilityCriteria":303,"healthyVolunteers":12,"sex":17,"minAge":281,"maxAge":19,"enrollmentInfo":304,"targetDuration":4,"studyType":23,"phases":306,"briefSummary":308,"conditions":309,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":313,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":48},"100406843","phase-4-pecs-study-for-cied-implantation-surgery-100406843","NCT04577690","PECS Study for CIED Implantation Surgery","Pectoral Nerve (PECS) Block for Cardiac Implantable Electronic Devices (CIED) Implantation Surgery","Inclusion Criteria:\n\n• All patients 3-18 years undergoing CIED surgery in the chest\n\nExclusion Criteria:\n\n* Children \\\u003C 3 years of age at time of procedure as bupivacaine is not licensed for this age group.\n* No parental or patient consent\n* Allergy to bupivacaine\n* Pregnancy or lactation\n* Any condition or diagnosis, that could in the opinion of the Principal Investigator or delegate interfere with the participant's ability to comply with study instructions, might confound the interpretation of the study results, or put the participant at risk.",{"count":305,"type":22},48,[307],"PHASE4","We aim to determine whether pectoral nerve block (PECS) performed after induction of anesthesia but before surgical incision results less opioid use in the post operative period compared with local infiltration alone in children undergoing Cardiac Implantable Electronic Device (CIED) surgery.",[310,311,312],"Pain, Postoperative","Child","Adolescent",{"date":246,"type":40},{"date":315,"type":40},"2019-12-01",{"date":317,"type":22},"2028-01-01",{"name":46,"class":47},{"id":320,"slug":321,"hasResults":12,"nctId":322,"briefTitle":323,"officialTitle":324,"acronym":4,"eligibilityCriteria":325,"healthyVolunteers":259,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":326,"targetDuration":4,"studyType":23,"phases":328,"briefSummary":329,"conditions":330,"keywords":334,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":339,"startDateStruct":341,"completionDateStruct":343,"leadSponsor":345,"locationsCount":4},"100632835","effect-of-anesthesia-equipment-position-on-anesthesiologists-performance-100632835","NCT07518849","Effect of Anesthesia Equipment Position on Anesthesiologists' Performance","The Effect of Anesthesia Equipment Position on Anesthesiologists' Crisis Management and Bag-valve-mask Ventilation Using Full Scale Simulation.","Inclusion Criteria:\n\n* All Department of Anesthesia residents (PGY4 or 5), fellows and staff are eligible to participate.\n\nExclusion Criteria:\n\n* Unwillingness to complete the simulated crisis and complete study questionnaires",{"count":327,"type":22},60,[25],"The purpose of this study is to determine if the position of the anesthesia machine affects the ability of anesthesiologists to manage a crisis situation and perform critical tasks. Participants will be asked to manage a simulated crisis situation using a manikin in the operating room. The anesthesia machine will be positioned either in an \"optimal\" or \"awkward\" manner for the anesthesiologist. The session will be video recorded and then analysed for various outcomes that reflect the anesthesiologist's performance. Participants will also perform a critical task, bag-valve-mask ventilation, on a manikin with the anesthesia machine in the optimal and awkward positions. The effectiveness of ventilation in each position will be compared. The results of this study may have implications for patient safety.",[331,332,333],"Anesthesia Ergonomics","Anesthesia Airway Management","Simulation in Training Center",[335,336,337],"Anesthesia","Ergonimcs","Simulation","2026-04-02",{"date":340,"type":40},"2026-04-09",{"date":342,"type":22},"2026-06",{"date":344,"type":22},"2026-12",{"name":46,"class":47},{"id":347,"slug":348,"hasResults":12,"nctId":349,"briefTitle":350,"officialTitle":351,"acronym":4,"eligibilityCriteria":352,"healthyVolunteers":259,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":353,"targetDuration":4,"studyType":23,"phases":355,"briefSummary":356,"conditions":357,"keywords":359,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":373,"locationsCount":4},"100632064","ai-assisted-endotracheal-intubation-100632064","NCT07508826","AI-assisted Endotracheal Intubation","AI-assisted Endotracheal Intubation in Children and Neonates: A Prospective Randomized Controlled Simulation Trial","Inclusion Criteria:\n\n* Any healthcare worker or trainee\n\nExclusion Criteria:\n\n* refusal to participate",{"count":354,"type":22},40,[25],"This study evaluates artificial intelligence (AI)-assisted videolaryngoscopy for endotracheal intubation in a simulated pediatric airway environment. Healthcare providers with varying levels of airway management experience will perform intubations on pediatric and neonatal mannequins using either AI-assisted videolaryngoscopy (larynGuide) or conventional videolaryngoscopy.\n\nParticipants will be randomized to perform intubation tasks using one of the two techniques. The primary outcome is the time required for successful intubation. Secondary outcomes include first-attempt success rate, number of attempts, airway visualization (POGO score), usability of the AI system measured by the System Usability Scale (SUS), and gaze tracking metrics evaluating user interaction with visual guidance.\n\nThis equivalence randomized controlled trial aims to determine whether AI-assisted videolaryngoscopy performs comparably to conventional videolaryngoscopy while potentially improving success rates and user experience.",[358],"Intubation Performance Using AI Versus Conventional Videolaryngoscope in a Mannikin",[360,361,362,363,364,365,366,93],"intubation","mannikin","simulation","artificial intelligence","larynguide","neonates","infants","2026-03-30",{"date":338,"type":40},{"date":370,"type":22},"2026-04-01",{"date":372,"type":22},"2026-11-30",{"name":46,"class":47},{"id":375,"slug":376,"hasResults":12,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":4,"eligibilityCriteria":380,"healthyVolunteers":12,"sex":17,"minAge":381,"maxAge":382,"enrollmentInfo":383,"targetDuration":4,"studyType":23,"phases":385,"briefSummary":386,"conditions":387,"keywords":391,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":399,"startDateStruct":400,"completionDateStruct":402,"leadSponsor":404,"locationsCount":48},"100544701","isoleucine-leucine-valine-and-tryptophan-requirements-in-tpn-fed-neonates-100544701","NCT06372314","Isoleucine, Leucine, Valine and Tryptophan Requirements in TPN Fed Neonates","Isoleucine, Leucine, Valine and Tryptophan Requirements in Total Parenteral Nutrition (TPN) Fed Neonates","Inclusion Criteria:\n\n1. Stable preterm babies that are growing and fully TPN fed (at least 90% of calories and protein).\n2. TPN providing adequate calories and protein as determined by attending physician and dietitian.\n3. Babies born ≥ 28 weeks gestation,\n4. ≤ 28 days chronological age at the time of the study,\n5. Birth weight and length appropriate for gestational age,\n6. Medically stable as determined by normal blood results and lack of a fever or infection,\n7. At least 3 days after surgery, if the baby had a surgery\n\nExclusion Criteria:\n\n1. Babies on mechanical ventilation, on low flow oxygen and CPAP.\n2. Small for gestational age,\n3. On medications known to affect protein and amino acid metabolism,\n4. Documented infection, fever\n5. Unstable medical condition\n6. Receiving enteral feeding providing \\> 10% of protein intake","1 Day","28 Days",{"count":384,"type":22},80,[25],"This project will be conducted in 2 hospitals in Brazil to assess the requirements for four essential amino acids in TPN fed neonates. Using the Carbon Oxidation method (indicator amino oxidation and direct amino acid oxidation method), the investigators will determine the requirement of each of the 4 amino acids.\n\nThe investigators will determine the requirement for Isoleucine, Leucine, Valine and Tryptophan. The investigators will recruit 18- 20 babies per amino acid study. Breath and urine samples will be collected to determine the oxidation of the indicator amino acid. The response of the indicator amino acid to changes in intake of the test amino acid (isoleucine, leucine, valine and tryptophan) will be analyzed by bi-phase linear mixed effect model to determine the breakpoint or mean requirement for each amino acid. It is hypothesized that the requirement for isoleucine, leucine, valine and tryptophan will be at least 50% lower than what is currently available in commercial solutions used for TPN feeding of neonates.",[388,389,390],"Neonates on TPN","Stable Neonates","Neonates Managed in the ICU",[392,365,393,394,395,396,397],"Neonates, Total pareteral nutrition (TPN), Isoleucine, Leucine, Valine, Tryptophan","parenteral nutrition","isoleucine","leucine","valine","tryptophan","2026-03-27",{"date":338,"type":40},{"date":401,"type":40},"2026-01-01",{"date":403,"type":22},"2027-12",{"name":46,"class":47},{"id":406,"slug":407,"hasResults":12,"nctId":408,"briefTitle":409,"officialTitle":410,"acronym":4,"eligibilityCriteria":411,"healthyVolunteers":12,"sex":17,"minAge":412,"maxAge":413,"enrollmentInfo":414,"targetDuration":4,"studyType":23,"phases":416,"briefSummary":417,"conditions":418,"keywords":421,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":426,"startDateStruct":427,"completionDateStruct":429,"leadSponsor":431,"locationsCount":4},"100631169","mrgfus-for-childhood-epilepsy-100631169","NCT07497178","MRgFUS for Childhood Epilepsy","A Prospective Cohort Study of High Intensity Focused Ultrasound Ablation for Brain Lesions in Children With Drug Resistant Epilepsy","Inclusion Criteria:\n\n• Age 4 - 17 years at time of enrollment • A confirmed diagnosis of epileptogenic lesion refractory to medication therapy. • Diagnosis of intractable epilepsy with failure after trial of two anti-epileptic medications. • Able to fit into a standard MRI unit. • Subjects with benign (WHO grade I) centrally located intracranial tumors which require clinical intervention and are known to carry minimal hemorrhage risk. • Patients with a head circumference \\>52cm and can tolerate frame-based stereotaxy. • Subjects should be on a stable dose of all condition-related medications for 30 days prior to study entry as determine by medical records. • The epileptogenic lesions (HH or other) can be targeted by the Exablate device. The lesion and region of treatment must be apparent on MRI and CT such that image fusion can delineate and model targeting when registered to the Exablate device.\n\nExclusion Criteria:\n\n• Any contraindication to MRI scanning • Pregnancy • Evidence of ethanol or substance abuse • Significant cardiac, respiratory, renal, or endocrine conditions (including arrhythmias) that increase procedural risk • History of abnormal bleeding disorders or hemorrhage • Use of anticoagulant, antiplatelet, or hemorrhage-associated medications","4 Years","17 Years",{"count":415,"type":22},20,[25],"The goal of this observational study is to learn if magnetic resonance imaging guided focused ultrasound (MRgFUS) can treat brain lesions causing epilepsy in children with drug resistant epilepsy. The main questions it aims to answer are:\n\nIs MRgFUS safe in children with drug-resistant epilepsy due to central brain lesions?\n\nDoes MRgFUS treatment reduce seizure frequency and severity and improve quality-of-life?\n\nResearchers will prospective assess outcomes following MRgFUS in children.\n\nParticipants undergoing MRgFUS will complete seizure diaries and questionnaires related to seizure severity and quality-of-life.",[419,420],"Drug Resistant Epilepsy","Epilepsy",[420,422,423,424],"DRE","MRI-guided focused ultrasound","MRgFUS","2026-03-23",{"date":398,"type":40},{"date":428,"type":22},"2026-03-01",{"date":430,"type":22},"2029-12-31",{"name":46,"class":47},{"id":433,"slug":434,"hasResults":12,"nctId":435,"briefTitle":436,"officialTitle":437,"acronym":4,"eligibilityCriteria":438,"healthyVolunteers":12,"sex":17,"minAge":260,"maxAge":413,"enrollmentInfo":439,"targetDuration":4,"studyType":23,"phases":440,"briefSummary":441,"conditions":442,"keywords":445,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":451,"startDateStruct":452,"completionDateStruct":454,"leadSponsor":456,"locationsCount":48},"100556766","deep-brain-stimulation-for-severe-self-injurious-behaviour-in-children-100556766","NCT06529380","Deep Brain Stimulation for Severe Self-Injurious Behaviour in Children","A Randomized Trial of Deep Brain Stimulation of the Nucleus Accumbens for Severe Self-Injurious Behaviours in Children","Inclusion Criteria:\n\n* Age 5-17 at the time of enrollment\n* DSM-5 diagnosis of Autism Spectrum Disorder\n* History of repetitive self-injurious behaviour, as reported by parents and documented on clinical assessment, either at the time of enrollment into the study or in prior medical records. The definition of self-injury is contextual, but requires ongoing, intermittent or continuous manifestation of self-mediated physical injury to the child.\n* Foreseeable risk of serious future self-harm.\n* Screening by study team for presence automatically reinforced self-injurious behaviour (ASIB) subtype 2 or subtype 3 based on caregiver history.\n* Failure or non-eligibility of medical therapy with ongoing repetitive self-injurious behaviours, at 6 months or more after initiation of therapy.\n* Parents or legal guardians, including caregivers, informed and able to provide written consent.\n* Able to comply with all testing, follow-up visits, and study appointments and protocols for 12 months following the end of the duration of the study.\n\nExclusion Criteria:\n\n* Substance dependence or abuse in the last 6 months, excluding caffeine and nicotine.\n* Any contraindication to MRI scanning.\n* Presence of cardiac arrhythmias, or other cardiac, respiratory, renal or endocrine conditions that may incur significant risk from a surgical procedure.\n* Pregnancy.",{"count":7,"type":22},[25],"Deep Brain Stimulation for the Treatment of Severe Refractory Self-Injurious Behaviour in Children with Autism Spectrum Disorder: A Randomized Trial\n\nTo evaluate the effectiveness of deep brain stimulation (DBS) of the nucleus accumbens for the treatment of severe refractory, repetitive self-injurious behavior (SIB) in children with Autism Spectrum Disorder. Secondary objectives are to examine the effects of DBS on subtypes of SIB through functional analysis.",[443,444],"Self-Injurious Behavior","Autism Spectrum Disorder",[446,447,448,449,450],"deep brain stimulation","DBS","ASD","SIB","nucleus accumbens",{"date":398,"type":40},{"date":453,"type":40},"2024-09-11",{"date":455,"type":22},"2026-12-31",{"name":46,"class":47},{"id":458,"slug":459,"hasResults":12,"nctId":460,"briefTitle":461,"officialTitle":462,"acronym":463,"eligibilityCriteria":464,"healthyVolunteers":259,"sex":17,"minAge":465,"maxAge":19,"enrollmentInfo":466,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":468,"conditions":469,"keywords":471,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":477,"lastUpdatePostDateStruct":478,"startDateStruct":480,"completionDateStruct":482,"leadSponsor":483,"locationsCount":48},"100627903","mri-assessment-of-lung-airways-in-cystic-fibrosis-evaluate-mris-ability-to-detect-changes-in-airway-structure--100627903","NCT07454681","MRI Assessment of Lung Airways in Cystic Fibrosis: Evaluate MRI's Ability to Detect Changes in Airway Structure .","Development of Magnetic Resonance Imaging Airway Segmentation to Assess and Monitor Cystic Fibrosis Lung Disease","UTE Airway MR","Group 1\n\nInclusion Criteria:\n\n* Participants must be greater than or equal to 6 years of age and not greater than 18 years of age.\n* Informed consent by patient or parent\u002Fguardian consent and participant assent when appropriate.\n* Able to perform reproducible spirometry\n\nExclusion Criteria:\n\n* Medical instability that would preclude the ability to undergo the required investigations\n* FEV1 % predicted \\\u003C 40%\n* Severe claustrophobia\n* Does not meet MRI screening criteria\n* Usage of oral antibiotics within 3 weeks prior to study visit\n* Known pulmonary disease\n\nGroup 2 Inclusion Criteria\n\n* Diagnosis of CF as evidenced by one or more clinical feature consistent with the CF phenotype or positive CF newborn screen\n* Participants must be greater than or equal to 6 years of age and not greater than 18 years of age.\n* Informed consent by patient or parent\u002Fguardian consent and participant assent when appropriate.\n* Able to perform reproducible spirometry\n\nExclusion Criteria\n\n* Medical instability that would preclude the ability to undergo the required investigations\n* FEV1 % predicted \\\u003C 40%\n* Severe claustrophobia\n* Does not meet MRI screening criteria\n* Worsening cough and\u002For sputum production within the past 3 days prior to study visit\n* The use of new oral and\u002For inhaled antibiotics within 3 weeks prior to study visit\n* Received intravenous antibiotics within 2 weeks prior to study visit\n* The use of supplementary oxygen\n* Status of post lung or another organ transplant","6 Years",{"count":467,"type":22},76,"This study is being done to determine whether MRI can produce high quality lung and airway images in healthy and CF patients and if MRI can be used to evaluate size and shape of the airways with computer assistance. This study will also repeat MRI experiments two years after the initial MRI scan to see if changes to airway size and shape are seen over time. In a subset of participants, we will investigate whether MRI results are repeatable and reproducible in the short-term one week after the initial MRI visit. This study will help understand if MRI based measurements of airway size and shape can be used as a monitoring tool that does not use x-ray radiation in patients with CF.",[470],"Cystic Fibrosis (CF)",[472,473,474,475,476],"Cystic Fibrosis","Magnetic Resonance Imaging","Ultrashort Echo Time","Multiple Breath Washout","Airways","2026-03-03",{"date":479,"type":40},"2026-03-06",{"date":481,"type":22},"2026-04-15",{"date":430,"type":22},{"name":46,"class":47},{"id":485,"slug":486,"hasResults":12,"nctId":487,"briefTitle":488,"officialTitle":489,"acronym":4,"eligibilityCriteria":490,"healthyVolunteers":12,"sex":17,"minAge":200,"maxAge":19,"enrollmentInfo":491,"targetDuration":4,"studyType":23,"phases":493,"briefSummary":494,"conditions":495,"keywords":499,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":477,"lastUpdatePostDateStruct":503,"startDateStruct":505,"completionDateStruct":507,"leadSponsor":509,"locationsCount":48},"100585463","timely-ordering-of-pharmacogenetic-testing-100585463","NCT06902688","Timely Ordering of Pharmacogenetic Testing","Timely Ordering of Pharmacogenetic Testing in Pediatric Oncology","Inclusion Criteria:\n\n* Inpatient at The Hospital for Sick Children\n* Between 6 months to 18 years old\n\nExclusion Criteria:\n\n* Prior pharmacogenetic testing and\u002For prior receipt of a targeted medication\n* Current Intensive Care Unit (ICU) admission\n* Expected hospital discharge is prior to midnight on the day of admission",{"count":492,"type":22},275,[25],"The goal of this trial is to learn if a machine learning (ML) model can help optimize drug therapy in the pediatric population. The main question\\[s\\] it aims to answer are whether a machine learning model predicting receipt of a targeted medication within the next three months:\n\n* Increases the offering of pharmacogenetic testing prior to receipt of a targeted medication\n* Increases the number of patients with pharmacogenetic results prior to receipt of a targeted medication\n* Increases the number of patients who have alteration in medication choice or dose based on pharmacogenetic results\n\nThis trial only focuses on the prediction and provision of participants with a high-risk of receiving a medication with a pharmacogenetic indication in the next three months.",[235,496,497,498],"Prediction Models","Pediatrics","Precision Medicine",[500,241,501,242,502],"precision medicine","pharmacogenetics","pediatrics",{"date":504,"type":40},"2026-03-05",{"date":506,"type":40},"2025-06-10",{"date":508,"type":22},"2027-06-10",{"name":46,"class":47},{"id":511,"slug":512,"hasResults":12,"nctId":513,"briefTitle":514,"officialTitle":515,"acronym":4,"eligibilityCriteria":516,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":517,"targetDuration":4,"studyType":23,"phases":519,"briefSummary":520,"conditions":521,"keywords":525,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":477,"lastUpdatePostDateStruct":530,"startDateStruct":531,"completionDateStruct":533,"leadSponsor":535,"locationsCount":48},"100584216","vomiting-prevention-in-children-with-cancer-100584216","NCT06886451","Vomiting Prevention in Children With Cancer","Prevention of Vomiting in Pediatric Oncology Inpatients Using Machine Learning","Inclusion Criteria:\n\n* All pediatric patients admitted to the oncology service at SickKids\n\nExclusion Criteria:\n\n* Pediatric patients admitted to the oncology service at SickKids that are discharged prior to prediction time",{"count":518,"type":22},1332,[25],"The goal of this single arm trial is to learn if a machine learning (ML) model predicting the risk of vomiting within the next 96 hours will impact vomiting outcomes in inpatient cancer pediatric patients.\n\nThe main questions it aims to answer are whether an ML model predicting the risk of vomiting within the next 96 hours will:\n\nPrimary\n\n1\\. Reduce the proportion with any vomiting within the 96-hour window\n\nSecondary\n\n1. Reduce the number of vomiting episodes\n2. Increase the proportion receiving care pathway-consistent care\n3. Impact on number of administrations and costs of antiemetic medications\n\nNewly admitted participants will have a ML model predict the risk of vomiting within the next 96 hours according to their medical admission information. The prediction will be made at 8:30 AM following admission. Pharmacists will be charged with bringing information about patients' vomiting risk to the attention of the medical team and implementing interventions.",[522,523,524],"Chemotherapy Induced Nausea and Vomiting","Quality of Life (QOL)","Pediatric Cancer",[526,527,528,529],"Vomiting","Machine learning","Quality of life","Pediatric oncology",{"date":504,"type":40},{"date":532,"type":40},"2025-03-18",{"date":534,"type":22},"2027-03-18",{"name":46,"class":47},{"id":537,"slug":538,"hasResults":12,"nctId":539,"briefTitle":540,"officialTitle":541,"acronym":4,"eligibilityCriteria":542,"healthyVolunteers":12,"sex":17,"minAge":260,"maxAge":19,"enrollmentInfo":543,"targetDuration":4,"studyType":23,"phases":545,"briefSummary":546,"conditions":547,"keywords":549,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":553,"lastUpdatePostDateStruct":554,"startDateStruct":555,"completionDateStruct":556,"leadSponsor":558,"locationsCount":4},"100627741","3d-ultrasound-in-hemophilic-ankles-100627741","NCT07452575","3D Ultrasound in Hemophilic Ankles","Can Ultrasound \"See\" What Clinicians Cannot in Hemophilic Arthropathy? Point-of-Care Ultrasound and Physical Examination Perspectives","Inclusion Criteria:\n\n* Diagnosis of hemophilia A or B or other bleeding disorders\n* Cooperative patients\n* Previous study joint bleed (by history) or suspicion of an acute joint bleed\n\nExclusion Criteria:\n\n* Co-morbid chronic illnesses causing osteoarticular findings\n* MRI contraindications",{"count":544,"type":22},11,[25],"The study examines whether a mechanical arm ultrasound system provides diagnostic accuracy comparable to expert-performed full ultrasound for detecting key joint components and whether it can reduce acquisition variability without compromising accuracy, as measured by false-positive and false-negative rates.",[548],"Hemophilia",[550,551,552,93],"hemophilia","ultrasound","mechanical arm","2026-03-02",{"date":504,"type":40},{"date":370,"type":22},{"date":557,"type":22},"2027-12-31",{"name":46,"class":47},{"id":560,"slug":561,"hasResults":12,"nctId":562,"briefTitle":563,"officialTitle":563,"acronym":4,"eligibilityCriteria":564,"healthyVolunteers":12,"sex":17,"minAge":465,"maxAge":19,"enrollmentInfo":565,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":567,"conditions":568,"keywords":570,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":575,"startDateStruct":577,"completionDateStruct":579,"leadSponsor":581,"locationsCount":48},"100392539","novel-pulmonary-function-measures-for-diagnosis-of-bronchiolitis-obliterans-syndrome-following-hematopoietic-stem-cell-transplantation-in-children-100392539","NCT04391335","Novel Pulmonary Function Measures for Diagnosis of Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem-Cell Transplantation in Children","Inclusion Criteria:\n\n* Male and female participants aged 6 -17.9 years old.\n* Received HSCT treatment at least 6 months prior to enrollment in study.\n* Participants should have an FEV1%pred value greater than 40%.\n* Participant understands the study procedures and is willing to participate in the study as indicated by signature on the informed consent or assent.\n* Participant must be able to perform a breath hold for 16s.\n* Participant meets MRI screening criteria\n\nExclusion Criteria:\n\n* Participant has had a cold or respiratory infection in the last four weeks.\n* Participant requires supplemental oxygen or has a daytime room air oxygen saturation ≤ 95%.\n* Participant is unable to perform spirometry or plethysmography maneuvers.\n* Participant is pregnant or lactating.",{"count":566,"type":22},15,"In this study, we will study 129Xe-MRI and LCI as tools for diagnosis of BOS in pediatric patients who have received Hematopoietic Stem Cell Transplantation (HSCT) and have been identified as eligible for this study. Participants will be required to have vital signs collected, complete breathing tests and complete an MRI. The MRI will require participants to perform breath holds in the MRI scanner with xenon gas while being coached by a research assistant.",[569],"Bronchiolitis Obliterans Syndrome",[571,572,573],"Stem cell transplantation","Xenon MRI","Lung","2026-02-26",{"date":576,"type":40},"2026-02-27",{"date":578,"type":40},"2020-10-20",{"date":580,"type":22},"2026-06-30",{"name":46,"class":47},{"id":583,"slug":584,"hasResults":12,"nctId":585,"briefTitle":586,"officialTitle":587,"acronym":4,"eligibilityCriteria":588,"healthyVolunteers":259,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":589,"targetDuration":4,"studyType":23,"phases":590,"briefSummary":592,"conditions":593,"keywords":595,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":597,"startDateStruct":598,"completionDateStruct":600,"leadSponsor":601,"locationsCount":48},"100265907","phase-2-xenon-129-and-inert-fluorinated-gas-lung-mri-study-of-healthy-volunteers-and-participants-with-pulmonary-disease-100265907","NCT02740868","Xenon-129 and Inert Fluorinated Gas Lung MRI: Study of Healthy Volunteers and Participants With Pulmonary Disease","Development of Hyperpolarized Xenon-129 and Inert Fluorinated Gas Lung Magnetic Resonance Imaging: Comparative Pilot Study of Healthy Volunteers and Participants With Pulmonary Disease","Inclusion Criteria:\n\n1. Participants male and female aged 8 years old and older.\n2. Participants have no smoking history.\n3. For participants with CF and asthma, a clinical diagnosis is necessary and they should be at their baseline level of symptom control based on history.\n4. Participants should have a FEV1%pred value greater than 40%.\n5. Participant understands the study procedures and is willing to participate in the study as indicated by signature on the informed consent or assent.\n6. Participant must be able to perform a breath hold for 20s or less.\n7. Participant able to perform reproducible pulmonary function tests (i.e., the 3 best acceptable spirograms have FEV1 values that do not vary more than 5% of the largest value or more than 100 ml, whichever is greater).\n\nFor the PEx sub-cohort, admission to the Hospital for Sick Children for a pulmonary exacerbation (based on clinical or pulmonary function assessment). Children who will be admitted and then discharged on home IV antibiotics may also be included in this study.\n\nExclusion Criteria:\n\n1. Participant is, in the opinion of the investigator, mentally or legally incapacitated, preventing informed consent\u002Fassent from being obtained, or cannot read or understand the written material.\n2. Participant has a history of cardiovascular disorders including coronary insufficiency, cardiac arrhythmias, severe hypertension.\n3. Other than for the PEx sub-cohort, participant has had a cold or respiratory infection in the last four weeks.\n4. Participant requires supplemental oxygen or has a daytime room air oxygen saturation ≤ 95%.\n5. Participant is unable to perform spirometry or plethysmography maneuvers.\n6. Participant is pregnant or lactating.\n7. In the investigator's opinion, participant suffers from any physical, psychological or other condition(s) that might prevent performance of the MRI, such as severe claustrophobia.\n8. Participant has an MRI incompatible device or any metal in their body which cannot be removed, including but not limited to pacemakers, neurostimulators, biostimulators, implanted insulin pumps, aneurysm clips, bio prosthetic, artificial limb, metallic fragment or foreign body, shunt, surgical staples (including clips or metallic sutures and\u002For ear implants).\n\n   \\-",{"count":21,"type":22},[591],"PHASE2","Aim of this study is to evaluate image quality and reproducibility of Xenon-129 and Inert fluorinated (19F) gas Magnetic Resonance Imaging (MRI) and to evaluate changes in lung structure and function in participants with cystic fibrosis (CF) and asthma compared to healthy controls.",[472,594],"Asthma",[596],"Magnetic Resonance Imaging,cystic fibrosis,asthma,healthy",{"date":553,"type":40},{"date":599,"type":4},"2015-08",{"date":455,"type":22},{"name":46,"class":47},{"id":603,"slug":604,"hasResults":12,"nctId":605,"briefTitle":606,"officialTitle":607,"acronym":608,"eligibilityCriteria":609,"healthyVolunteers":12,"sex":17,"minAge":610,"maxAge":413,"enrollmentInfo":611,"targetDuration":4,"studyType":23,"phases":612,"briefSummary":613,"conditions":614,"keywords":616,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":628,"lastUpdatePostDateStruct":629,"startDateStruct":631,"completionDateStruct":632,"leadSponsor":633,"locationsCount":634},"100619530","dexamethasone-vs-placebo-in-children-and-youth-hospitalized-for-orbital-cellulitis-100619530","NCT07345819","Dexamethasone vs. Placebo in Children and Youth Hospitalized for Orbital Cellulitis","Dexamethasone vs. Placebo in Children and Youth Hospitalized for Orbital Cellulitis: the VISION Pilot Randomized Clinical Trial","VISION","Inclusion Criteria:\n\n1. Age 2.00 months -17.99 years (prior to 18th birthday)\n2. Confirmed or suspected diagnosis of orbital cellulitis as determined by the attending physician, medical team, and\u002For delegate's clinical judgement, based on one or more features of orbital cellulitis (i.e., ophthalmoplegia, pain and\u002For limitation with extraocular movements, chemosis, blurred vision, eye swollen shut, and\u002For proptosis).\n3. Scheduled to be admitted or admitted to hospital for less than 36 hours.\n4. Informed consent provided in accordance with institutional policies\n\nExclusion Criteria:\n\n1. Transferred directly from outside hospital inpatient setting to a participating hospital site's inpatient setting with over 36 hours having passed since admission to outside hospital. If within 36 hours, patient is eligible.\n2. Treatment with IV or PO systemic corticosteroids within 1 week of presentation\n3. Recent hospital admission for orbital cellulitis within 1 week of presentation\n4. Current systemic fungal infection\n5. Contraindication for dexamethasone or components of dexamethasone IV formulation\n6. Clinically relevant varicella exposure in the previous 21 days\n7. Previous enrollment in this study\n8. No telephone\u002Fmobile\u002Femail\n9. Poor mastery of English, or medical interpreter not available for languages other than English","2 Months",{"count":21,"type":22},[25],"The goal of this pilot randomized controlled trial is to understand whether we can successfully conduct a larger definitive clinical trial in the future. The current pilot study will test various aspects of the larger trial and help us improve its design if needed. The investigators are mainly interested in knowing whether they can (1) recruit enough patients, (2) administer the intervention, and (3) collect all the data needed from patients. The definitive randomized controlled trial will assess if dexamethasone is superior to placebo for treating children and youth hospitalized with orbital cellulitis.",[615],"Orbital Cellulitis",[617,618,619,620,621,622,623,624,625,103,243,626,93,627],"orbital cellulitis","pilot trial","pilot RCT","preseptal cellulitis","periorbital cellulitis","dexamethasone","corticosteroid","inpatient","RCT","paediatric","youth","2026-01-16",{"date":630,"type":40},"2026-01-21",{"date":370,"type":22},{"date":557,"type":22},{"name":46,"class":47},2,{"id":636,"slug":637,"hasResults":12,"nctId":638,"briefTitle":639,"officialTitle":640,"acronym":4,"eligibilityCriteria":641,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":642,"targetDuration":4,"studyType":23,"phases":643,"briefSummary":644,"conditions":645,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":646,"lastUpdatePostDateStruct":647,"startDateStruct":649,"completionDateStruct":651,"leadSponsor":653,"locationsCount":48},"100566131","pain-caregiver-resource-paincare-100566131","NCT06651190","Pain Caregiver Resource (PainCaRe)","Building mHealth Parent Capacity to Manage Pain in Young Children With Cancer: A Pilot Randomized Controlled Trial","1. Be the primary caregiver, or person assuming the majority of care activities, for a child aged 2-11 years undergoing cancer treatment and experiencing above mild pain (≥3\u002F10) in the week preceding study enrolment (pain measured by self or caregiver proxy using a validated numerical 11-point rating scale).\n2. Be able to speak and read English.",{"count":354,"type":22},[25],"Pain is a problem for children with cancer, especially when they are outside of the hospital setting. Younger children with cancer are particularly vulnerable to undermanaged pain because of their inability to self-report pain and their reliance on parents for treatment. One method to help these children to get the best care possible is through the use of smartphone-based mHealth solutions. Smartphone apps can provide treatment advice to patients experiencing pain in real-time and in any environment. This research will use a phased and user-centered approach with family caregivers to co-design and co-evaluate the new cancer Pain Caregiver Resource (PainCaRe) app to achieve the following aims: (1) high-fidelity software development and usability refinement; (2) evaluation of trial feasibility and preliminary effectiveness in a pilot randomized controlled trial (RCT); and (3) systematic analysis of caregiver app usage patterns to refine PainCaRe for optimal engagement prior to a future RCT.",[524],"2025-12-05",{"date":648,"type":40},"2025-12-15",{"date":650,"type":22},"2026-04",{"date":652,"type":22},"2027-04",{"name":46,"class":47},{"id":655,"slug":656,"hasResults":12,"nctId":657,"briefTitle":658,"officialTitle":659,"acronym":4,"eligibilityCriteria":660,"healthyVolunteers":12,"sex":17,"minAge":661,"maxAge":19,"enrollmentInfo":662,"targetDuration":4,"studyType":23,"phases":663,"briefSummary":664,"conditions":665,"keywords":670,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":675,"lastUpdatePostDateStruct":676,"startDateStruct":678,"completionDateStruct":680,"leadSponsor":681,"locationsCount":682},"100294904","phase-2-rct-of-olanzapine-for-control-of-civ-in-children-receiving-highly-emetogenic-chemotherapy-100294904","NCT03118986","RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy","Randomized Controlled Trial of Olanzapine for the Control of Chemotherapy-induced Vomiting in Children Receiving Highly Emetogenic Chemotherapy","Planned receipt of HEC or cyclophosphamide ≥ 1 g\u002Fm2\u002Fday (≥ 33 mg\u002Fkg\u002Fday) for cancer treatment or autologous or allogeneic HSCT conditioning.81,82 Examples of HEC are: busulfan IV (myeloablative dosing), carboplatin ≥175mg\u002Fm²\u002Fdose, cisplatin ≥12mg\u002Fm²\u002Fdose, cytarabine ≥3g\u002Fm²\u002Fday, melphalan \\>140mg\u002Fm², methotrexate ≥12g\u002Fm²\u002Fdose and thiotepa ≥300mg\u002Fm²\u002Fdose.\n\nPlan for inpatient admission from administration of first study drug dose until 24 hours following administration of last study drug dose.\n\nBody weight of at least 12.5 kg\n\n2.5 to \\\u003C 18 years of age. Note that the minimum age requirement corresponds to an approximate body weight of 12.5 kg.\n\nSamples for all laboratory tests will be obtained within one week prior to administration of the first chemotherapy dose of the study chemotherapy block or the first HSCT conditioning dose:\n\n* Plasma creatinine within 1.5 times the upper limit of normal for age.\n* Amylase within age-appropriate limits\n* Plasma conjugated bilirubin within ≤ 3x upper limit of normal for age unless attributable to Gilbert's Syndrome\n* ALT ≤ 5x upper limit of normal for age\n\nBaseline ECG within the month prior to study drug administration without known clinically significant abnormalities including pathologic prolongation of QTc\n\nA plan for scheduled, round-the-clock receipt of ondansetron, granisetron or palonosetron for antiemetic prophylaxis during administration of chemotherapy or HSCT conditioning.\n\nNegative pregnancy test if female of childbearing potential\n\nPatients of childbearing potential must consent to use adequate contraception (males and females) or agree to practice abstinence\n\nParent or child able to speak a language in which the (modified Pediatric Adverse Event Rating Scale (PAERS) is available.\n\nOptional: Child participants in the optional assessment of nausea severity must be 4 to 18 years of age. Child and a parent\u002Fguardian must be English, Spanish or French-speaking. The Pediatric Nausea Assessment Tool58 (PeNAT) is validated in English-speaking children 4 to 18 years old with an English-speaking parent\u002Fguardian and has been translated into Spanish and French. The MAT is available in English, Spanish and French.","30 Months",{"count":263,"type":22},[591],"Chemotherapy-induced nausea and vomiting (CINV) are among the most bothersome symptoms during cancer treatment according to children and their parents. Most children receiving highly emetogenic chemotherapy (HEC), including those receiving hematopoietic stem cell transplant (HSCT) conditioning, experience CIV despite receiving antiemetic prophylaxis. Olanzapine improves CINV control in adult cancer patients, has a track record of safe use in children with psychiatric illness, does not interact with chemotherapy and is inexpensive. We hypothesize that the addition of olanzapine to standard antiemetics will improve chemotherapy-induced vomiting (CIV) control in children receiving highly emetogenic chemotherapy",[666,667,668,669],"Vomiting in Infants and\u002For Children","Nausea","Hematopoietic System--Cancer","Oncology",[671,672,93,94,673,674],"olanzapine","vomiting","bone marrow transplant","supportive care","2025-10-03",{"date":677,"type":40},"2025-10-08",{"date":679,"type":40},"2017-08-10",{"date":650,"type":22},{"name":46,"class":47},10,""]